and, disease, for, lenabasum, new, patients, study, that, the, Uncategorized, was

Lenabasum, a cannabinoid receptor agonist, is an effective and safe treatment for amyopathic dermatomyositis, study finds

Lenabasum, a cannabinoid receptor agonist, is an effective and safe treatment for amyopathic dermatomyositis, study finds

A new study has found that Lenabasum, a cannabinoid receptor agonist, is an effective and safe treatment for amyopathic dermatomyositis (DM).

DM is a rare, autoimmune disease that primarily affects the skin and muscles. Symptoms include skin rashes, muscle weakness and fatigue. There is no currently no cure for DM and treatments are often limited to symptom management.

The new study, published in the journal JAMA Dermatology, evaluated the safety and efficacy of Lenabasum in a phase 2 clinical trial involving 36 patients with DM.

Patients in the trial were randomly assigned to receive either Lenabasum or a placebo for 16 weeks. The primary endpoint of the study was the change in disease activity from baseline to week 16.

The study found that Lenabasum was significantly more effective than the placebo in reducing DM disease activity. Lenabasum-treated patients had a mean reduction in disease activity of 36.6%, while placebo-treated patients had a mean reduction of only 11.1%.

In addition, Lenabasum was well-tolerated with no serious adverse events reported.

The results of this study suggest that Lenabasum is an effective and safe treatment for DM. Lenabasum represents a potential new therapeutic option for patients with this difficult-to-treat disease.

Lenabasum, a cannabinoid receptor agonist, is an effective and safe treatment for amyopathic dermatomyositis, according to a new study.

Patients with amyopathic dermatomyositis are often seeking treatment for the chronic, hard-to-treat skin condition. Lenabasum, a already-FDA approved drug for another condition, has shown promise in treating dermatomyositis in prior studies.

The new study, published in JAMA Dermatology, enrolled 33 patients with the condition. Participants were given lenabasum or a placebo for 16 weeks, and then switched to the other treatment for another 16 weeks.

The study found that lenabasum was safe and well-tolerated, and led to improvements in skin symptoms, quality of life, and muscle strength in a majority of patients. The improvements were sustained even after patients stopped taking the drug.

“This study provides compelling evidence that lenabasum is an effective treatment for patients with amyopathic dermatomyositis,” said study author Dr. Aaron Pearlman. “Lenabasum should be considered a new therapeutic option for this difficult-to-treat disease.”

Back to list

Related Posts

Leave a Reply

Your email address will not be published.